Terms: = Endocrine gland cancer AND TFE3, RCCP2, 7030, ENSG00000068323, TFEA AND Treatment
5 results:
1. Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
Fekete JT; Ősz Á; Pete I; Nagy GR; Vereczkey I; Győrffy B
Gynecol Oncol; 2020 Mar; 156(3):654-661. PubMed ID: 31973910
[TBL] [Abstract] [Full Text] [Related]
2. Differentiation of hypovascular pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinoma using contrast-enhanced computed tomography.
Ren S; Chen X; Wang Z; Zhao R; Wang J; Cui W; Wang Z
PLoS One; 2019; 14(2):e0211566. PubMed ID: 30707733
[TBL] [Abstract] [Full Text] [Related]
3. Cytogenetic and dosimetric effects of (131)I in patients with differentiated thyroid carcinoma: comparison between stimulation with rhTSH and thyroid hormone withdrawal treatments.
da Silva MA; Valgôde FG; Gonzalez JA; Yoriyaz H; Guimarães MI; Ribela MT; Buchpiguel CA; Bartolini P; Okazaki K
Radiat Environ Biophys; 2016 Aug; 55(3):317-28. PubMed ID: 27013085
[TBL] [Abstract] [Full Text] [Related]
4. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
[TBL] [Abstract] [Full Text] [Related]
5. Value of FDG PET/CT in patients with treated ovarian cancer and raised CA125 serum levels.
Palomar A; Nanni C; Castellucci P; Ambrosini V; Montini GC; Allegri V; Pettinato C; Al-Nahhas A; Soriano A; Grassetto G; Rubello D; Fanti S
Mol Imaging Biol; 2012 Feb; 14(1):123-9. PubMed ID: 21240639
[TBL] [Abstract] [Full Text] [Related]
